Quarterly report (Form 10-Q)
Bristol Myers Squibb 10-Q for Quarter ended Mar 31, 2026
Filing excerpt
International revenues increased 11% during the first quarter of 2026, primarily due to higher demand across the Growth Portfolio and for Eliquis, partially offset by generic erosion within the remainder of the Legacy Portfolio.